Rheumatology International

, Volume 35, Issue 8, pp 1307–1310 | Cite as

Correlation between P2X7 receptor gene polymorphisms and gout

Review Article - Genes and Disease
First Online:
Received:
Accepted:

Abstract

Not all patients with hyperuricemia will develop acute gouty arthritis, indicating that other initiating factors need to be considered. The P2X7 receptor is an adenosine triphosphate-gated nonselective cation channel that has also been suggested to be a proinflammatory receptor. In the immune system, the P2X7 receptor is involved in the processing and release of various proinflammatory cytokines, including interleukin-1β (IL-1β), IL-18 and tumor necrosis factor-α (TNF-α). IL-1β is a central cytokine in the initiation of the acute inflammatory response, which plays a key role in the pathogenesis of gout and the pathology of acute gouty arthritis. This review will explore single-nucleotide polymorphisms in the P2X7R gene [including rs1718119 (Ala348Thr), rs208294 (His155Tyr), rs3751143 (Glu496Ala), rs28360457 (Arg307Gln) and rs2230911 (Thr357Ser)] and their correlation with the incidence of gout. We conclude that P2X7R gene polymorphisms impact the secretion of IL-1β and thus play a vital role in the pathogenesis of gout.

Keywords

Gout P2X7 receptor Single-nucleotide polymorphisms 
This is a preview of subscription content, log in to check access.

References

  1. 1.
    Robinson PC, Horsburgh S (2014) Gout: joints and beyond, epidemiology, clinical features, treatment and co-morbidities. Maturitas 78(4):245–251PubMedCrossRefGoogle Scholar
  2. 2.
    Tao JH, Zhang Y, Li XP (2013) P2X7R: a potential key regulator of acute gouty arthritis. Semin Arthritis Rheum 43(3):376–380PubMedCrossRefGoogle Scholar
  3. 3.
    Ferrari D, Pizzirani C, Adinolfi E et al (2006) The P2X7 receptor: a key player in IL-1 processing and release. J Immunol 176(7):3877–3883PubMedCrossRefGoogle Scholar
  4. 4.
    Kingsbury SR, Conaghan PG, McDermott MF (2011) The role of the NLRP3 inflammasome in gout. J Inflamm Res 4:39–49PubMedCentralPubMedGoogle Scholar
  5. 5.
    Steiger S, Harper JL (2014) Mechanisms of spontaneous resolution of acute gouty inflammation. Curr Rheumatol Rep 16(1):392PubMedCrossRefGoogle Scholar
  6. 6.
    Van den Berg WB (2000) Arguments for interleukin 1 as a target in chronic arthritis. Ann Rheum Dis 59(Suppl 1):i81–i84PubMedCentralPubMedCrossRefGoogle Scholar
  7. 7.
    Rock KL, Latz E, Ontiveros F et al (2010) The sterile inflammatory response. Annu Rev Immunol 28:321–342PubMedCentralPubMedCrossRefGoogle Scholar
  8. 8.
    Rock KL, Kataoka H, Lai JJ (2013) Uric acid as a danger signal in gout and its comorbidities. Nat Rev Rheumatol 9(1):13–23PubMedCentralPubMedCrossRefGoogle Scholar
  9. 9.
    Pope RM, Tschopp J (2007) The role of interleukin-1 and the inflammasome in gout: implications for therapy. Arthritis Rheum 56(10):3183–3188PubMedCrossRefGoogle Scholar
  10. 10.
    Martinon F (2010) Mechanisms of uric acid crystal-mediated autoinflammation. Immunol Rev 233(1):218–232PubMedCrossRefGoogle Scholar
  11. 11.
    Terkeltaub RA, Schumacher HR, Carter JD et al (2013) Rilonacept in the treatment of acute gouty arthritis: a randomized, controlled clinical trial using indomethacin as the active comparator. Arthritis Res Ther 15(1):R25PubMedCentralPubMedCrossRefGoogle Scholar
  12. 12.
    Schlesinger N, Alten RE, Bardin T et al (2012) Canakinumab for acute gouty arthritis in patients with limited treatment options: results from two randomised, multicentre, active-controlled, double-blind trials and their initial extensions. Ann Rheum Dis 71(11):1839–1848PubMedCrossRefGoogle Scholar
  13. 13.
    Jarvis MF, Khakh BS (2009) ATP-gated P2X cation-channels. Neuropharmacology 56(1):208–215PubMedCrossRefGoogle Scholar
  14. 14.
    Chataigneau T, Lemoine D, Grutter T (2013) Exploring the ATP-binding site of P2X receptors. Front Cell Neurosci 7:273PubMedCentralPubMedCrossRefGoogle Scholar
  15. 15.
    Rumney RM, Wang N, Agrawal A et al (2012) Purinergic signalling in bone. Front Endocrinol (Lausanne) 3:116Google Scholar
  16. 16.
    Gever JR, Cockayne DA, Dillon MP et al (2006) Pharmacology of P2X channels. Pflugers Arch 452(5):513–527PubMedCrossRefGoogle Scholar
  17. 17.
    Trautmann A (2009) Extracellular ATP in the immune system: more than just a “danger signal”. Sci Signal 2(56):pe6PubMedCrossRefGoogle Scholar
  18. 18.
    Eleftheriadis T, Pissas G, Karioti A et al (2013) Uric acid induces caspase-1 activation, IL-1β secretion and P2X7 receptor dependent proliferation in primary human lymphocytes. Hippokratia 17(2):141–145PubMedCentralPubMedGoogle Scholar
  19. 19.
    Alves LA, Bezerra RJ, Faria RX et al (2013) Physiological roles and potential therapeutic applications of the P2X7 receptor in inflammation and pain. Molecules 18(9):10953–10972PubMedCrossRefGoogle Scholar
  20. 20.
    Kvist TM, Schwarz P, Jørgensen NR (2014) The P2X7 receptor: a key player in immune-mediated bone loss? Sci World J 2014:954530. doi: 10.1155/2014/954530 CrossRefGoogle Scholar
  21. 21.
    Lenertz LY, Gavala ML, Zhu Y et al (2011) Transcriptional control mechanisms associated with the nucleotide receptor P2X7, a critical regulator of immunologic, osteogenic, and neurologic functions. Immunol Res 50(1):22–38PubMedCentralPubMedCrossRefGoogle Scholar
  22. 22.
    Andrei C, Margiocco P, Poggi A et al (2004) Phospholipases C and A2 control lysosome-mediated IL-1 beta secretion: implications for inflammatory processes. Proc Natl Acad Sci USA 101(26):9745–9750PubMedCentralPubMedCrossRefGoogle Scholar
  23. 23.
    Skaper SD (2011) Ion channels on microglia: therapeutic targets for neuroprotection. CNS Neurol Disord Drug Targets 10(1):44–56PubMedCrossRefGoogle Scholar
  24. 24.
    Stokes L, Fuller SJ, Sluyter R et al (2010) Two haplotypes of the P2X(7) receptor containing the Ala-348 to Thr polymorphism exhibit a gain-of-function effect and enhanced interleukin-1beta secretion. FASEB J 24(8):2916–2927PubMedCrossRefGoogle Scholar
  25. 25.
    Cabrini G, Falzoni S, Forchap SL et al (2005) A His-155 to Tyr polymorphism confers gain-of-function to the human P2X7 receptor of human leukemic lymphocytes. J Immunol 175(1):82–89PubMedCrossRefGoogle Scholar
  26. 26.
    Gu BJ, Zhang W, Worthington RA et al (2001) A Glu-496 to Ala polymorphism leads to loss of function of the human P2X7 receptor. J Biol Chem 276(14):11135–11142PubMedCrossRefGoogle Scholar
  27. 27.
    Wesselius A, Bours MJ, Arts IC et al (2012) The P2X(7) loss-of-function Glu496Ala polymorphism affects ex vivo cytokine release and protects against the cytotoxic effects of high ATP-levels. BMC Immunol 13:64PubMedCentralPubMedCrossRefGoogle Scholar
  28. 28.
    Shemon AN, Sluyter R, Fernando SL et al (2006) A Thr357 to Ser polymorphism in homozygous and compound heterozygous subjects causes absent or reduced P2X7 function and impairs ATP-induced mycobacterial killing by macrophages. J Biol Chem 281(4):2079–2086PubMedCrossRefGoogle Scholar
  29. 29.
    Gu BJ, Sluyter R, Skarratt KK et al (2004) An Arg307 to Gln polymorphism within the ATP-binding site causes loss of function of the human P2X7 receptor. J Biol Chem 279(30):31287–31295PubMedCrossRefGoogle Scholar
  30. 30.
    Roger S, Mei ZZ, Baldwin JM et al (2010) Single nucleotide polymorphisms that were identified in affective mood disorders affect ATP-activated P2X7 receptor functions. J Psychiatr Res 44(6):347–355PubMedCrossRefGoogle Scholar
  31. 31.
    Amaral FA, Costa VV, Tavares LD et al (2012) NLRP3 inflammasome-mediated neutrophil recruitment and hypernociception depend on leukotriene B(4) in a murine model of gout. Arthritis Rheum 64(2):474–484PubMedCrossRefGoogle Scholar
  32. 32.
    Portales-Cervantes L, Niño-Moreno P, Doníz-Padilla L et al (2010) Expression and function of the P2X(7) purinergic receptor in patients with systemic lupus erythematosus and rheumatoid arthritis. Hum Immunol 71(8):818–825PubMedCrossRefGoogle Scholar
  33. 33.
    Sorge RE, Trang T, Dorfman R et al (2012) Genetically determined P2X7 receptor pore formation regulates variability in chronic pain sensitivity. Nat Med 18(4):595–599PubMedCentralPubMedCrossRefGoogle Scholar

Copyright information

© Springer-Verlag Berlin Heidelberg 2015

Authors and Affiliations

  1. 1.Department of RheumatologyNingbo No.2 HospitalNingbo, ZhejiangChina
  2. 2.School of MedicineNingbo UniversityNingbo, ZhejiangChina

Personalised recommendations